Wang Eric J, Dolomisiewicz Edward, Karri Jay, Tontisirin Nuj, Cohen Steven P
Department of Anesthesiology and Critical Care Medicine, Division of Pain Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Physical Medicine and Rehabilitation, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Korean J Pain. 2023 Jul 1;36(3):299-315. doi: 10.3344/kjp.23130.
The discovery and development of antimicrobial therapies represents one of the most significant advancements in modern medicine. Although the primary therapeutic intent of antimicrobials is to eliminate their target pathogens, several antimicrobials have been shown to provide analgesia as a secondary benefit. Antimicrobials have demonstrated analgesic effects in conditions that involve dysbiosis or potential subclinical infection (, chronic low back pain with Modic type 1 changes; chronic prostatitis/chronic pelvic pain; irritable bowel syndrome; inflammatory bowel disease; functional gastrointestinal disorders/dyspepsia; myalgic encephalomyelitis/chronic fatigue syndrome), and might even prevent the chronification of pain after acute infections that are associated with excessive systemic inflammation (, post COVID-19 condition/long Covid, rheumatic fever). Clinical studies often assess the analgesic effects of antimicrobial therapies in an observational manner, without the ability to identify causative relationships, and significant gaps in the understanding remain regarding the analgesic potential of antimicrobials. Numerous interrelated patient-specific, antimicrobial-specific, and disease-specific factors altogether contribute to the perception and experience of pain, and each of these requires further study. Given worldwide concerns regarding antimicrobial resistance, antimicrobials must continue to be used judiciously and are unlikely to be repurposed as primary analgesic medications. However, when equipoise exists among several antimicrobial treatment options, the potential analgesic benefits of certain antimicrobial agents might be a valuable aspect to consider in clinical decision-making. This article (the second in a two-part series) aims to comprehensively review the evidence on the prevention and treatment of chronic pain using antimicrobial therapies and suggest a framework for future studies on this topic.
抗菌疗法的发现与发展是现代医学中最重大的进步之一。尽管抗菌药物的主要治疗目的是消灭其目标病原体,但已证实几种抗菌药物具有镇痛的次要益处。抗菌药物在涉及菌群失调或潜在亚临床感染的病症(如伴有Modic 1型改变的慢性下腰痛、慢性前列腺炎/慢性盆腔疼痛、肠易激综合征、炎症性肠病、功能性胃肠疾病/消化不良、肌痛性脑脊髓炎/慢性疲劳综合征)中已显示出镇痛作用,甚至可能预防与全身性炎症过度相关的急性感染后疼痛的慢性化(如新冠后状况/长新冠、风湿热)。临床研究通常以观察性方式评估抗菌疗法的镇痛效果,无法确定因果关系,并且在抗菌药物的镇痛潜力方面仍存在重大认知差距。众多相互关联的患者特异性、抗菌药物特异性和疾病特异性因素共同影响疼痛的感知和体验,这些因素中的每一个都需要进一步研究。鉴于全球对抗菌药物耐药性的关注,抗菌药物必须继续谨慎使用,不太可能被重新用作主要镇痛药物。然而,当几种抗菌治疗方案存在平衡时,某些抗菌药物的潜在镇痛益处可能是临床决策中值得考虑的一个有价值的方面。本文(系列文章的第二篇)旨在全面综述使用抗菌疗法预防和治疗慢性疼痛的证据,并为该主题的未来研究提出一个框架。